Perceptual Decision Making Under Conditions of Visual Uncertainty (NCT01845883) | Clinical Trial Compass
WithdrawnNot Applicable
Perceptual Decision Making Under Conditions of Visual Uncertainty
Stopped: Initiating PI has left the institution, and no participants have been enrolled for the interventional trial.
United States0Started 2013-04
Plain-language summary
In this proposal the investigators have three Specific Aims using human patient populations as model systems; 1) identify a role for the Basal Ganglia (BG) in perceptual decision making; 2) determine whether the Basal Ganglia contribute to decision making under conditions of visual uncertainty; 3) determine whether the cerebellum plays a role in perceptual decision-making under conditions of visual uncertainty. The investigators designed experiments using healthy humans and humans with diseases known to affect the Basal Ganglia and the cerebellum, Parkinson's Disease, dystonia and non-dystonic cerebellar damage. With this approach the investigators will test the following hypotheses: 1) Patients with Parkinson's Disease and dystonia will have more difficulty than healthy controls making perceptual decisions when faced with sensory uncertainty; when sensory information is certain, patients will show improved decision-making but will still be impaired relative to healthy humans. Hypothesis 2: If ambiguous sensory information is aided by prior information, patients with Parkinson's Disease and dystonia will be unable to use the prior (bias/memory) information to inform their decisions. Hypothesis 3: Deep Brain Stimulation (DBS) of Basal Ganglia structures will improve the ability of patients to use prior information to inform their decisions when faced with sensory uncertainty. Hypothesis 4: Both cholinergic and dopaminergic medical therapies will improve the ability of patients to use prior information to inform their decisions. Hypothesis 5: Patients with non-dystonic cerebellar damage will be similar to healthy controls in performance of a perceptual decision making task in conditions of visual uncertainty. The overarching framework of this application is that the same mechanisms (D1 striatal synaptic plasticity) that operate in reward learning play a role in learning and using stimulus priors in a perceptual decision-making task when faced with uncertainty. Because Parkinson's Disease and dystonia share deficits in striatal circuitry, the patient deficits on this task will be similar. Because non-dystonic cerebellar patients do not have dysfunction of striatal circuits, they will show no deficits in the ability to use stimulus priors to guide choices in uncertain conditions. In the event these patients do show deficits, this is will provide evidence for an unexplored role for the cerebellum in perceptual decision-making.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Group 1 - Age and Sex matched healthy controls:
* Age 18-80 Years
Group 2 - Patients with Parkinson's Disease - No DBS:
* "on meds" and "off meds" (tested in separate sessions) - total of 2 sessions
* Age 45-80 Years
* Unified PD rating scale (UPDRS)
* Mini mental health Status (MMHS)
Group 3 - Patients with Parkinson's Disease already consented for DBS (STN):
* Age 45-80 Years
* Unified PD rating scale (UPDRS)
* Mini mental health Status (MMHS)
Group 4 - Patients with Parkinson's Disease already consented for DBS (GPi):
* Age 45-80 Years
* Unified PD rating scale (UPDRS)
* Mini mental health Status (MMHS)
Group 5 - Patients with Cervical Dystonia - No DBS
* Age 30-80 years
* Fahn-Marsden dystonia rating scale (FMDRS)
* Mini mental health Status (MMHS)
Group 6 - Patients with Generalized Dystonia (Ach) - No DBS:
* Age 30-80 years
* Fahn-Marsden dystonia rating scale (FMDRS)
* Mini mental health Status (MMHS)
Group 7 - Patients with Dystonia already consented for DBS (GPi):
* Age 30-80 years
* Fahn-Marsden dystonia rating scale (FMDRS)
* Mini mental health Status (MMHS)
Group 8 - Patients Cerebellar Stroke
* Age 30-80 Years
* Routine neuro exam
* Mini mental health Status (MMHS)
Group 9 - Patients Cerebellar Ataxia
* Age 30-80 Years
* Routine neuro exam
* Mini mental health Status (MMHS)
Exclusion Criteria:
* Visual impairment or ocular motility disorder Inability to sit for the 30 minute task plus 20-30 minute instruction time, setup, …
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial was listed as 'withdrawn' — can you tell me whether it was withdrawn due to safety concerns, funding issues, or something else, and whether a similar study is currently recruiting that we should consider instead?
2Since this study was measuring perceptual decision-making under visual uncertainty, how relevant would that kind of research be to my specific diagnosis — whether Parkinson's disease, dystonia, or ataxia — and what would participating in that type of cognitive or visual testing actually involve day-to-day?
3This trial is listed as Phase NA, which often means it's observational or behavioral rather than testing a treatment — so what would I or my family member actually gain from participating, since it doesn't appear to involve a new therapy?
4Given that this study is no longer active, are there other ongoing research studies focused on how movement disorders like mine affect perception or cognition that my care team would recommend I look into?
5Before pursuing any research study, would you recommend I first make sure my current treatment plan for my condition is optimized, so that any participation in future research reflects my best baseline health?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Choice performance - % correct responses out of total number of trials
Timeframe: at the end of each testing session - 2 hours